Epithelial-mesenchymal transition (EMT) is a developmental program that is associated with esophageal squamous cell carcinoma (ESCC) progression and metastasis. Recently, C/EBPb has been reported to be an EMT inducer in cancer. However, the detailed molecular mechanisms remain unclear. Here, we report for the first time, that the truncated CCAAT-enhancer-binding protein b (C/EBPb) LIP isoform is abnormally overexpressed and correlated with cancer metastasis in clinical specimens of human ESCC. Furthermore, we demonstrate that C/EBPb LIP mediates epithelial growth factor (EGF)-induced EMT and increases migration and invasion of esophageal cancer cells in a manner that is dependent on miR-203 inactivation. Finally, we identified miR-203 as a direct target of C/EBPb LIP. Disruption of C/EBPb LIP attenuated the EGF-mediated decrease in miR-203, whereas overexpression of C/ EBPb LIP alone markedly suppressed miR-203. In addition, we demonstrated that C/EBPb LIP inhibited miR-203 transcription by directly interacting with a conserved distal regulatory element upstream of the miR-203 locus, and in doing so, orchestrated chromatin remodeling. In conclusion, our results have revealed a new regulatory mechanism that involves C/EBPb-LIP-mediated downregulation of miR-203, which plays a key role in EMT and metastasis.
INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal cancer in Asia, and is characterized by a high incidence and mortality rate. Both an aggressive potential and distant metastasis are the major causes of treatment failure (Enzinger and Mayer, 2003) .
Epithelial-mesenchymal transition (EMT) is an essential process during the malignant transformation of cancer, particularly during metastasis. However, the molecular mechanisms of EMT in ESCC are not fully understood. In the past several decades, a series of transcription factors, including b-catenin, snail, slug and twist, have been shown to be involved in EMT of several cancers, and might be promising therapeutic targets. The crucial EMT modulators largely vary in different types of cancer, and therefore, the central contextdependent regulatory molecules participating in EMT in ESCC should be clearly defined.
The CCAAT/enhancer binding protein b (C/EBPb) is a regulator of cell proliferation and differentiation and is implicated in many biological activities including inflammatory responses (Armstrong et al., 2009 ) and adipogenesis (Ceseña et al., 2008) . Emerging evidence has shown that C/EBPb exists in three isoforms: LAP1, LAP2 and LIP, and that dysregulation of C/EBPb is markedly correlated with malignancy of several tumors, including glioma, Wilms tumors, renal cell carcinoma and ovarian tumor (Homma et al., 2006; Li et al., 2005; Oya et al., 2003; Sundfeldt et al., 1999) .
In a previous study, Bundy et al. discovered that C/EBPb LAP2 overexpression induced a normal human mammary epithelial cell line (MCF10A) to undergo EMT and acquire an invasive phenotype (Bundy and Sealy, 2003) . Nevertheless, the underlying mechanisms through which C/EBPb LAP2 very effectively instigates EMT are still obscure. Moreover, it remains unknown which isoform is dominantly expressed in ESCC and whether the corresponding role is relevant in the process of EMT.
Apart from transcription factors, increasing evidence indicates that micro (mi)RNAs also regulate key genetic programs in EMT. In particular, miR-203 is defined as a tumor suppressor for controlling EMT and metastasis in several cancers (Davis et al., 2006; Mega et al., 2005; Moes et al., 2012; Saini et al., 2011; Zhang et al., 2014; Zhang et al., 2011) . Additionally, various research groups studying miRNA expression profiles have revealed that miR-203 decreases in esophageal cancer (Feber et al., 2008; Mathé et al., 2009) . Our previous study found that the CpG island of the miR-203 promoter is unmethylated in both ESCC and corresponding normal tissues (Chen et al., 2012) , indicating that the decrease in miR-203 was not due to CpG methylation in ESCC. Thus, the underlying mechanism of miR-203 downregulation still remains to be explored. Bioinformatics tools benefit our aims of identifying potential transcription factors that regulate miR-203 expression. Using in silico analysis, we found two putative C/EBPb-binding motifs located within 5 kb upstream of the transcription start site of the mir-203 locus. Accordingly, we hypothesized that C/EBPb LIP mediated the downregulation of miR-203, which participates in EMT and tumor progression.
In the present study, we examined the association between C/EBPb dysregulation and ESCC and found that abnormal upregulation of C/EBPb LIP was significantly related to metastasis. Next, we showed that elevated C/EBPb LIP contributes to the EMT process, which is usually the first step in tumor metastasis. Furthermore, the role of C/EBPb LIP in mediating EMT is dependent on miR-203 inactivation. Additionally, we characterized miR-203 as a direct target of C/EBPb LIP. Two C/EBPb-binding motifs reside within a conserved non-coding sequence of mir-203 located upstream of the distal regulatory element. By directly binding to the responsive element, C/EBPb LIP affected chromatin remodeling and repressed miR-203 expression. Taken together, we have identified a new regulatory mechanism of C/EBPb LIP wherein it decreases miR-203 expression, which then accounts for C/EBPb LIP-mediated EMT and metastasis in ESCC.
RESULTS

Elevated C/EBPb LIP and the LIP:LAP ratio in ESCC are associated with metastasis
We examined C/EBPb protein levels in esophageal tumor tissues and the corresponding adjacent non-tumor tissues from 36 surgical patients by immunoblotting ( Fig. 1A ; supplementary material Fig. S1C ). We found that cancerous tissues exhibited significantly higher C/EBPb LIP protein levels as compared with the corresponding adjacent normal tissues by paired analysis (28/ 36, 77.8%, Fig. 1B ). The unpaired analysis for the C/EBPb LIP:LAP ratio showed a dramatic elevation in ESCC (n536) as compared with normal tissues (n536) (P,0.05, Fig. 1C ). The LIP:LAP ratio in patients with lymph node metastasis (13/36) was higher than that without lymph node metastasis (23/36) (P,0.01, Fig. 1D ). This result suggests that C/EBPb LIP might be involved in esophageal cancer metastasis and the increase in the C/EBPb LIP:LAP ratio might lead to more aggressive forms of ESCC. In addition, we performed immunofluorescence to assess overall C/ EBPb expression in normal versus ESCC tissue sections and found that C/EBPb was elevated and co-expressed with vimentin in ESSC samples (supplementary material Fig. S1B ).
The C/EBPb LIP and LIP:LAP ratios are upregulated during EGF-induced EMT in an ESCC model To evaluate the relationship between C/EBPb and EMT, we first established an epithelial growth factor (EGF)-induced EMT model in two typical esophageal epithelial cell lines. It was found that both EC109 and EC9706 cells exhibited typical polygonal cobblestone epithelial morphology when grown in normal culture, whereas exposure to 50 ng/ml EGF induced obvious morphological changes, including a more scattered pattern of growth, and some cells exhibited an elongated spindle shape that extended from the edge of the cell sheet ( Fig. 2A) . Apart from these morphological changes, the EMT model was also confirmed by evidence of increased expression of mesenchymal markers (bcatenin and vimentin), and decreased expression of epithelial markers (ZO-1 and pan-cytokeratin) (Fig. 2B) . We assayed C/ EBPb cellular protein levels over a 48-h period in EGF-treated EC109 and EC9706 cells. Western blot analysis of whole-cell extracts revealed that the expression of the LAP1 and LAP2 isoforms were at a very low level in resting cells, and gradually increased to peak levels by 12 h (EC9706) or 24 h (EC109) of EGF stimulation, but sharply declined to lower levels by 48 h. In contrast, maximal expression of the LIP isoform occurred later at 24 h, and remained at a relatively high level by 48 h of EGF (A) Western blotting analysis of C/EBPb LAP and LIP isoforms in cancerous (Ca) (n536) and adjacent non-cancerous (N) (n536) tissues from ESCC patients. Representative western blots for C/EBPb (LAP, LIP) in paired samples are shown. (B) Paired expression analysis of the C/EBPb LIP:LAP ratio with paired tumorigenic (n536) and corresponding normal tissues (n536) from the same patient. The relative level of LIP:LAP ratio was calculated according to the grayscale densities of the western blot bands. The result represents the LIP:LAP ratio in tumor tissues relative to that in the corresponding normal tissues. All data were normalized to GAPDH. (C) The LIP:LAP ratio was significantly upregulated in ESCC (n536) as compared with non-tumor tissues (n536) by unpaired expression analysis. (D) The LIP:LAP ratio was significantly increased in ESCCs with lymph node metastasis (Nx) (n513) compared with that without lymph node metastasis (N0) (n523). *P,0.05. stimulation (Fig. 2B ). In addition, after densitometric analysis and subsequent calculation of the LIP:LAP ratio (where LAP represents LAP1 plus LAP2), we found that the LIP:LAP ratio was upregulated in a time-dependent manner (Fig. 2C) . We also found increased total transcripts of the three C/EBPb isoforms (LAP1, LAP2 and LIP) in parallel with protein levels (Fig. 2D ).
The ability of C/EBPb LIP to promote EMT and increase cell migration and invasion is dependent on miR-203 inactivation
To evaluate the role of C/EBPb in EMT, we examined cell morphology and EMT markers after altering C/EBPb status. Three small interfering RNAs (siRNAs) were developed to avoid off-target effects (si-1, si-2 and si-3) and all of them gave strong C/EBPb LIP depletion without affecting the expression levels of the housekeeping protein GAPDH, and only slightly reducing the level of C/EBPb LAP isoforms (Fig. 3A) . Interestingly, knockdown of C/EBPb LIP impaired EGF-induced morphological changes in EC109 cells and led to a more scattered and round-like phenotype. In addition, LIP knockdown also impaired vimentin induction after EGF treatment (Fig. 3B ). In accordance with these observations, western blotting analysis showed that C/EBPb LIP depletion significantly increased the expression of the epithelial markers ZO-1 (also known as TJP1) and pan-cytokeratin, and decreased the expressions of the mesenchymal markers b-catenin and vimentin after EGF treatment (Fig. 3A) . However, the effect of C/EBPb LIP disruption on the EMT markers was reversed by the miR-203 inhibitor 203inhi (Fig. 3C, si-1+203inhi group) . Similar to the effects of C/EBPb LIP depletion, the miR-203 mimic blocked EMT-related marker protein alterations after EGF treatment (Fig. 3C, 203 mimic group) . By contrast, ectopic expression of C/ EBPb LIP altered EMT-related marker levels in a dose-dependent manner (Fig. 3C , LIP group; supplementary material Fig. S2A ). Meanwhile, forced overexpression of C/EBPb LAP1 and C/EBPb LAP2 did not change EMT-related marker levels (supplementary material Fig. S2B,C) . Collectively, these data suggest that C/ EBPb LIP mediates EMT by inactivating miR-203.
To assess the role of LIP in migration and invasion, EC109 cells were transfected with LIP-expressing vector (pcDNA3-LIP) or empty vector (pcDNA3.1). The results showed that overexpression of C/EBPb LIP significantly enhanced the migration and invasion potential of EC109 cells, by 281% and 272%, respectively (Fig. 3D) . Next, to investigate whether miR-203 participated in cellular migration and invasion, and whether LIP promoted migration and invasion through miR-203, miR-203 mimic (203mimic) or mimic control (mimic ctrl) were cotransfected with LIP-expressing vector (pcDNA3-LIP) or empty vector (pcDNA3.1). The expressions of miR-203 and LIP were determined by quantitative real-time PCR (qRT-PCR) and western blotting, respectively (supplementary material Fig.  S3A,B) . We found that miR-203 mimic decreased migration and invasion in C/EBPb-LIP-overexpressing cells (Fig. 3E , 203mimic+pcDNA3-LIP group), whereas in pcDNA3.1-transfected cells, miR-203 mimic had no effect on migration and invasion ability (Fig. 3E, 203mimic+pcDNA3 .1 group). The results suggest that, following C/EBPb LIP overexpression, a decrease in miR-203 is required to enhance cellular motility and invasiveness.
Additionally, to verify the relationship between miR-203 expression and metastasis, we assessed miR-203 levels in the clinical ESCC samples. The results showed that miR-203 expression was downregulated in the 36 ESCC tumor samples (P50.0480, supplementary material Fig. S4A ), but there was no significant difference between non-metastatic and metastatic tumors (P50.0832, supplementary material Fig. S4B ). This could be because of the limited sample sizes, and investigation on a larger scale is needed to confirm this result.
Two potential C/EBPb-binding sites are located in the conserved region of the miR-203 distal promoter
In preliminary studies, bioinformatics tools (such as the 'chip mapper' public database) were utilized to determine the putative downstream targets of C/EBPb. In silico analyses revealed that two C/EBPb-binding motifs were located 3 kb upstream from the transcription start site of miR-203. Both sites (nt 23628 to 23615 and 23266 to 23253) were in a conserved non-coding sequence, as suggested by the UCSC TFBS track, which predicts conserved transcription-factor-binding sites, using the tfloc program and data sets from the Transfac Matrix and Factor databases (Fig. 4A) . The binding motifs of the evolutionarily conserved transcription factors tend to reside in the conserved non-coding sequence within the regulatory regions of their putative target genes.
To determine whether C/EBPb LIP regulates the expression of miR-203 by binding directly to the corresponding genomic sequences, we performed chromatin immunoprecipitation (ChIP) (E) miR-203 mimic (203mimic) or mimic control (mimic ctrl) was co-transfected with LIP expressing vector (pcDNA3-LIP) or empty vector (pcDNA3.1) in EC109 cells and at 24 h post-transfection cells were harvested for a transwell migration assay and the matrigel invasion assay. Cell numbers that crossed the membrane were calculated; at least six fields were counted for statistical analysis. Experiments were performed in triplicate and all data are expressed as the mean6s.d. *P,0.05 compared with control group (mimic ctrl+pcDNA3.1 group); experiments with control EC109 cells and EGF-induced transformed EC109 cells. We observed that the induced C/ EBPb LIP protein bound directly to the two canonical C/EBPbbinding sites (203R1 and 203R2) in the mir-203 locus that were in the conserved non-coding sequence, but did not bind to unrelated negative regions (Fig. 4B , Neg.ctrl1 and Neg.ctrl2). In addition, we found that C/EBPb depletion decreased the enrichment of this regulatory region sequence upon EGF treatment (Fig. 4B , si-1+EGF group). Representative PCR gels for the ChIP analysis are provided in supplementary material Fig.  S4C . This observation indicates that EGF enhances the direct interaction between C/EBPb and the conserved elements in the mir-203 locus.
EGF increases C/EBPb LIP-LIP homodimer binding to the miR-203 regulatory elements C/EBPb functions as homo-or hetero-dimers (LAP-LAP, LAP-LIP or LIP-LIP). To further determine which of the dimers binds to the miR-203 regulatory regions, we performed an electrophoretic mobility shift assay (EMSA). The results showed that complexes containing homodimers of LAP (LAP-LAP, upper complex) and LIP (LIP-LIP, bottom complex), and heterodimers of LAP and LIP (LAP-LIP, middle band) were detected by using a positive control C/EBP probe (lane 3). The addition of antibodies specific for C/EBPb (anti-b) caused a supershift of these complexes (Fig. 4C, lane 6) . In EC109 cells, LAP-LIP heterodimers were the main form that bound to miR-203 regulatory regions in the control group (Fig. 4C , lane 1 and lane 4), and EGF treatment caused a dramatic increase in the binding of LIP-LIP homodimers ( The wild-type luciferase reporter containing C/EBPb-binding motifs in the mir-203 conserved non-coding sequence (CNS-Luc) and a mutant luciferase reporter with corresponding mutated sequences (mCNS-Luc) were constructed as shown in Fig. 4D . Reporter assays showed that C/EBPb LIP decreased the activity of wild-type CNS-Luc without affecting mCNS-Luc activity (Fig. 4E) . Hence, the downregulation of miR-203 by C/EBPb LIP depends directly on these cognate recognition sites in the distal binding element of the mir-203 locus.
We further evaluated the correlation between C/EBPb LIP and miR-203 in both EC109 and EC9706 cells. We found that EGF increased C/EBPb LIP expression (Fig. 2B,D) , whereas it decreased miR-203 levels (Fig. 5A) . Furthermore, knockdown of C/EBPb LIP attenuated the suppression on miR-203 mediated by EGF (Fig. 5B) . Ectopic overexpression of C/EBPb LIP was sufficient to decrease miR-203 in a dose-dependent manner (Fig. 5D) . Additionally, we examined a set of known downstream gene targets of miR-203 and found that disruption of C/EBPb LIP decreased the expressions of these genes (encoding E2F1, BIRC5, snail and slug). However, the expression of these genes could be partially rescued by using miR-203 inhibitor in addition to the siRNA (Fig. 5C) , suggesting that the effect of suppressing C/ EBPb LIP on the target genes is dependent on miR-203. Collectively, our data indicate that C/EBPb LIP represses endogenous miR-203 expression and increased the expression of miR-203 target genes.
C/EBPb LIP affects the chromatin condensation at the regulatory regions of the miR-203 locus Gene expression alterations are influenced by chromatin status, which is marked by some histone modifications. Thus, we speculated as to how C/EBPb LIP functions as a transcriptional repressor. It is also unclear whether EGF is implicated in chromatin remodeling in C/EBPb-LIP-mediated miR-203 suppression. We therefore assessed classical histone markers for open chromatin (H3K4me1) or condensed chromatin (H3K9me3, H3K27me3). ChIP assays demonstrated that EGF promoted a more condensed, silenced chromatin structure by decreasing the amount of the active chromatin marker H3K4me1 (Fig. 6A,  scr+EGF group) , while increasing the expression of the suppressive chromatin markers H3K9me3 and H3K27me3 (Fig. 6B,C, scr+EGF group) . Silencing of C/EBPb LIP led to the erasure of these chromatin changes (Fig. 6, si-1+EGF group) . These data suggested that C/EBPb LIP contributes to EGFinduced downregulation of miR-203, and did so by maintaining a concordant chromatin microenvironment that suppressed the enlistment of basic transcriptional machinery.
DISCUSSION
In the present study, we identified a C/EBPb-LIP-miR-203 regulatory axis that plays a pivotal role in EMT and metastasis of ESCC. To our knowledge, the transcription factor C/EBPb has three isoforms, LAP1, LAP2 and LIP, which exist in different forms and exert different functions. C/EBPb LAP1 mediates the recruitment of the nucleosome-remodeling complex SWI-SNF, which activates silenced genes through chromatin remodeling and increases access of transcription factors to their binding sites (Kowenz-Leutz and Leutz, 1999) . LAP1 is selectively activated through a redox switch to regulate the lipopolysaccharide-induced expression of the IL-6 gene (Su et al., 2003) . C/EBPb LAP2 can promote the growth of mammary epithelial cells (MECs) (Bundy and Sealy, 2003) . In addition, LAP2 can lead to cell cycle arrest in keratinocytes (Zhu et al., 1999) and fibroblasts (Johnson, 2005) . It has been reported that targeted expression of LIP in the mouse mammary gland leads to hyperplasia and tumorigenesis (Zahnow et al., 2001) . Other evidence has shown that LIP activates several genes involved in the lipopolysaccharide-mediated acute-phase response in mouse liver (An et al., 1996) .
The dysregulation of C/EBPb might be strongly correlated with tumor progression in several human tumors Sundfeldt et al., 1999; Zahnow, 2009 ), but the results have been inconsistent. The upregulation of C/EBPb LIP has been reported in colorectal cancer (Rask et al., 2000) and breast cancer (Albergaria et al., 2013). Here, we report that C/EBPb LIP and the resultant LIP:LAP ratio were specifically elevated in ESCC tissues and correlated with tumor metastasis (Fig. 1) . However, owing to the limited follow-up data on these esophageal cases, we could not correlate C/EBPb LIP levels with either the survival rate or metastatic recurrence.
EMT is an essential event during tumor metastasis, and understanding this process will provide great promise for cancer therapy (Mehlen and Puisieux, 2006) . The overall roles of C/ EBPb as a positive or negative EMT modulator remain controversial. Bundy and Sealy have performed an infection with recombinant retrovirus selectively encoding C/EBPb LAP2 in a normal human mammary epithelial cell line (MCF10A). These C/EBP LAP2-overexpressing breast cancer cells underwent an EMT process and acquired an invasive phenotype (Bundy and Sealy, 2003) . Another report has also identified C/ EBPb as a positive regulator of mesenchymal transformation in human glioma (Carro et al., 2010) . By contrast, using an established model of TGF-b-induced EMT in mouse mammary gland epithelial cells, Johansson et al. have discovered that C/ EBPb inhibited EMT in a breast cancer model (Johansson et al., 2013) . In our study, we demonstrated that C/EBPb LIP positively mediated the EMT process (Fig. 3A,B) . The inconsistent results regarding C/EBPb playing either a positive or a negative role during the EMT process might be attributed to different roles played by C/EBPb isoforms in different cancers. Bundy et al. have shown that C/EBPb LAP1 is the only isoform detected in normal human mammary tissue and that, whereas C/EBPb LAP1 is absent in breast cancer cell lines, overexpression of the dominant isoform C/EBPb LAP2 is sufficient to induce MCF10A cells to undergo EMT (Bundy and Sealy, 2003) . We detected only one larger isoform and one smaller isoform in the immunoblots of patient sample ESCC biopsies. Moreover, C/EBPb LIP was detected in most tumor tissues ( Fig. 1A; supplementary material Fig. S1C ), whereas in transformed ESCC lines (EC109 and EC9706), all three C/EBPb forms, LAP1, LAP2 and LIP, were detected (Fig. 2B) . The different expression of the C/EBPb isoforms might have individual biological significance in different tissue types or cellular contexts. Presently, it is difficult for us to investigate the mechanism underlying differential expression of C/EBPb isoforms between esophageal cell lines and esophageal squamous cell carcinoma tissues, but our results provide more information regarding the three isoforms in ESCC cell lines and patient samples, and provide evidence to support the differential expression of those three isoforms in different cancers.
Downregulation of miR-203 has been reported in a number of different cancers including ESCC (Castilla et al., 2011; Chen et al., 2011; Chiang et al., 2011; Chim et al., 2011; Feber et al., 2008) . The loss of function caused by miR-203 dysregulation is involved in more aggressive tumor behaviors. In our in vitro EMT model, miR-203 was dramatically decreased in response to EGF treatment (Fig. 5A) , which is consistent with the observations by Sonkoly and colleagues (Sonkoly et al., 2010) . In particular, miR-203 directly reversed EMT in mammary epithelial cells and inhibited migration and invasiveness in prostate cancer cells (DeCastro et al., 2013; Viticchie et al., 2011) . Consistently, we observed that the miR-203 mimic significantly rescued the decrease in epithelial markers and the increase in mesenchymal markers after EGF treatment (Fig. 3C, 203mimic group) , showing anti-EMT properties.
Although miR-203 participated in LIP-mediated migration and invasion (Fig. 3E, 203mimic+pcDNA3 -LIP group), in pcDNA3.1-transfected cells, the miR-203 mimic had no effect on the ability of cells to migrate and invade (Fig. 3E,  203mimic+pcDNA3.1 group) . A possible reason might be the high basal expression of miR-203 in EC109 cells. After overexpression of LIP, which suppressed miR-203 levels, miR-203 mimic did change migration and invasion ability. We previously compared miR-203 expression in different esophageal cell lines and found that miR-203 had differing basal levels of expression in these cells. EC109 cells had higher basal expression than EC9706 cells (supplementary material Fig. S3D ). In addition, the level of miR-203 expression in the two cell lines correlates with migration and invasion potential; EC109 cells had a significantly lower migration and invasion potential than EC9706 cells (supplementary material Fig. S3C ). Furthermore, we assessed the migration and invasion ability of EC109 cells after altering miR-203 status. The results showed that compared with inhibitor control, transfection of miR-203 inhibitor significantly enhanced the migration and invasion ability of EC109 cells (supplementary material Fig. S3E ), suggesting that the suppressive effect of miR-203 on migration and invasion depends on the cellular context.
The target molecules of miR-203 have been well elucidated regarding the mechanisms of anti-EMT function, including a cohort of pro-metastatic genes such as those encoding BIRC5, snail and slug (Ding et al., 2013; Furuta et al., 2010; Moes et al., 2012; Saini et al., 2011; Zhang et al., 2011) . However, the reason for miR-203 dysregulation in tumors is poorly understood. In the present study, we found that miR-203 has an inverse expression pattern with C/EBPb LIP in EGF-induced transformed esophageal cancer cells (Fig. 5A) . Depletion of C/EBPb LIP erased the suppression of miR-203 that was mediated by EGF (Fig. 5B) and influenced miR-203 downstream target genes (Fig. 5C) . Conversely, overexpression of C/EBPb LIP alone inhibited miR-203 expression (Fig. 5D) , indicating that miR-203 is a downstream target molecule of C/EBPb LIP. ChIP assays demonstrated that C/EBPb LIP could directly bind to the conserved element of the mir-203 locus (Fig. 4B) . C/EBPb LIP frequently functions as homo-or hetero-dimers and acts as a dominant-negative inhibitor of transcription (Zahnow, 2009 ), and we found that, before EGF treatment, the main form binding to the miR-203 regulatory regions was LAP-LIP, and that EGF treatment increased LIP-LIP homodimer binding (Fig. 4C) . Consistently, our study showed that C/EBPb LIP was a negative modulator of miR-203, as the reporter assays clearly indicated (Fig. 4E) . However, sporadic evidence suggests that C/ EBPb LIP can also be a transcriptional activator, as is demonstrated in breast cancer lines MCF-7 and SKBR3 in which C/EBPb LIP upregulated the expression of the chemokine receptor CXCR4 . The varying roles of C/EBPb LIP are likely dependent on requisite partners for target specificity and combinatorial control of gene regulation (Gade et al., 2012) in different cellular contexts.
In summary, we confirm that C/EBPb LIP is upregulated and is correlated with metastasis in ESCC. Our in vitro functional studies demonstrated that C/EBPb LIP promotes EMT and increases migration and invasion of esophageal cancer cells in a manner that is dependent on miR-203 inactivation. Mechanistically, the elevated C/EBPb LIP associates with the predicted C/EBPb-binding motifs located ,3 kb upstream of the miR-203 transcription start site and functions as a crucial regulator in the epigenetic machinery linking altered chromatin and reduced miR-203 expression in response to EGF. Our data provide novel insights into the C/EBPb-LIP-miR-203 regulatory axis that plays a pivotal role in EMT and metastasis of ESCC. We envision that C/EBPb LIP might represent an attractive target for therapeutic intervention.
MATERIALS AND METHODS
Clinical tissues and reagents
ESCC samples were collected from 36 patients who underwent surgery at the Thoracic and Cardiac Surgery unit of Southwest Hospital in Chongqing, China from January 2008 to January 2009. All patients had definite pathology diagnosis, and none had received radiotherapy or chemotherapy before surgery. The corresponding non-tumorigenic tissues were grossly normal tissues that were located 5 cm from the esophageal cancer (supplementary material Fig. S1A ). All samples were obtained following informed and written consent and with institutional review board approval from the hospital according to the Declaration of Helsinki (2000) . The specimens were instantly divided into several pieces and stored at 280˚C after surgery.
Recombinant human EGF was obtained from Peprotech (Rocky Hill, NJ). The following antibodies (Abs) were used: rabbit polyclonal Ab against pan-cytokeratin and mouse monoclonal Ab to vimentin (Santa Cruz Biotechnology Inc., Santa Cruz, CA); rabbit monoclonal Abs to ZO-1 and b-catenin (Cell Signaling Technology, Danvers, MA); rabbit monoclonal Ab against C/EBPb (Abcam, Cambridge, MA), which identifies residues in the C-terminus of rat C/EBPb and is specific for the three C/EBPb isoforms (LAP1, LAP2 and LIP); and mouse monoclonal Abs to H3K4me1, H3K9m3 and H3K27me3 (Upstate Biotechnology, Lake Placid, NY, USA). Lipofectamine 2000 was obtained from Invitrogen. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from HyClone Laboratories (Logan, UT, USA). All oligonucleotides were synthesized by the BGI Company (Beijing, China). Taq DNA polymerases and the luciferase assay system were obtained from Promega (Madison, WI). The miR-203inhibitor, miR-203mimic and negative controls were obtained from Shanghai GenePharma (Shanghai, China). The sequences were as follows: miR-203 inhibitor, 59-CUAGUGGUCCUAAACAUUUCAC-39; inhibitor control, 59-CAGUACUUUUGUGUAGUACAA-39; miR-203 mimic, sense 59-GUGAAAUGUUUAGGACCACUAG-39, anti-sense 59-AGU-GGUCCUAAACAUUUCACUU-39; mimic control, sense 59-UUCUCC-GAACGUGUCACGUTT-39, anti-sense 59-ACGUGACACGUUCGGA-GAATT-39.
Plasmids
Expression vectors encoding pcDNA3-LIP were constructed as previously described (Wang et al., 2008) . We sub-cloned the distal element (nt 23692 to 23220), including both of the predicted C/EBPb recognition sites of the miR-203-encoding gene into the luciferase expression pGL3-promoter plasmid. The two binding motifs were mutated using the QuikChangeH site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The resulting constructs were verified by DNA sequencing, and designated as CNS-Luc and mCNS-Luc (Fig. 4E) . Primers are listed in supplementary material Table S1 .
Cell culture and EGF treatment
The human esophageal cancer cell lines EC109 and EC9706 were obtained from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China. Cells were maintained in DMEM supplemented with 10% (v/v) FBS, at 37˚C, and under 5% CO 2 in air. Cells at 50% confluence were serum-starved for 12 h before EGF treatment (50 ng/ml under serum-free conditions).
RNA interference
To downregulate C/EBPb expression in vitro, three siRNA sequences (21 nt) targeting human C/EBPb mRNA were selected from three positions of C/EBPb cDNA sequence and checked to ensure the lack of repetitive elements or homologies to other genes. The three siRNA target sequences were: si-1, 59-GAAGACCGTGGACAAGCAC-39 (common to translated regions for LAP1, LAP2 and LIP); si-2, 59-GAAGTGGCCAACTTC-TACT-39 (common to translated regions for LAP1 and LAP2); and si-3, 59-AAACCAACCGCACATGCAGAT-39 (common to untranslated regions for LAP1, LAP2 and LIP). Scrambled RNAs were also generated as negative controls. Scrambled RNAs were: sense 59-UUCUCCGAACGUG-UCACGUTT-39 and anti-sense 59-ACGUGACACGUUCGGAGAATT-39. All siRNA duplexes were chemically synthesized by the Shanghai GenePharma Company (Shanghai, China).
Cell transfection and luciferase reporter assay
Cells were transfected with Lipofectamine 2000 according to the manufacturer's instructions. To transfect the pcDNA3-LIP expression vector, cells were plated 18 h before transfection at a density of 1.2610 5 cells/well in 2 ml of fresh culture medium in six-well culture plates. Next, 5 ml of Lipofectamine 2000 was incubated with 2 mg of plasmid in 500 ml of Opti-MEM medium for 20 min at room temperature (22˚C). Cells were transfected by changing the medium to 500 ml of Opti-MEM, which contained the plasmids plus Lipofectamine 2000. The total DNA concentration for each transfection was matched with pcDNA3.1 (Invitrogen). For the luciferase reporter assay, cells were plated at a density of 1610 4 cells/well in 96-well culture plates and then transfected as described above. Briefly, 0.1 mg of CNS-Luc or mCNS-Luc and 0.001 mg of the Renilla luciferase expression vector pRL-TK (Promega, which was used as an internal control), were transfected into cells. For co-transfection experiments, 0.02 mg of the pcDNA3-LIP expression plasmid was included. In addition, the expression vector pcDNA3.1 was used as a negative control to evaluate the effects of LIP on CNS-Luc.
Firefly and Renilla luciferase activities were measured using the DualLuciferase Reporter Assay kit. Firefly luciferase activities were normalized to Renilla luciferase controls.
For siRNA transfections, chemosynthesized siRNAs were dissolved in 150 ml of RNase-free water to obtain a concentration of 20 mM. Effective interference sequences are listed in supplementary material Table S1 , according to previous studies (Goransson et al., 2005) . Cells were seeded at a density of 1.2610 5 cells/well in six-well culture plates 1 day before transfection, and then transfection was performed with siRNA or scrambled RNA at a final concentration of 50 nM. Cells were allowed to grow for 24 h after transfection and then treated as indicated.
RNA extraction and quantitative real-time PCR analysis
Total RNA was extracted using RNAiso reagent (Takara) according to the manufacturer's instructions and quantified using a NanoDrop spectrophotometer (Thermo Scientific). MiR-203 expression was measured using the All-in-One miRNA qRT-PCR detection kit according to the manufacturer's instructions (GeneCopoeia). For C/ EBPb detection, 300 ng of total RNA was converted to cDNA and specific primers for total transcripts of three C/EBPb isoforms (LAP1, LAP2 and LIP) were used, the cDNA was amplified using SYBR premix ex TaqTM (TaKaRa). The PCR conditions were 95˚C for 3 min, followed by 40 cycles of 95˚C for 20 s, 60˚C for 30 s and 72˚C for 20 s. The expression of miR-203 and C/EBPb were normalized against the relative expression of U6 snRNA and GAPDH, respectively. The relative amounts of mRNAs were calculated using the comparative threshold cycle method. A list of the primers used is shown in supplementary material Table S1 .
Western blotting
For a total protein analysis, cells were harvested and lysed in T-PER Tissue Protein Extraction Reagent (Pierce Chemical Company) with freshly added PMSF. The concentration of proteins was quantified by the Enhanced BCA Protein Assay Kit (BeyonTime). Equal amount of proteins (50 mg) were separated by SDS-PAGE (10% gel) and electrotransferred onto a PVDF membrane (Millipore). After blocking with 5% skimmed (low-fat) milk, the membrane was incubated with a primary antibody and was then stained with the appropriate horseradishperoxidase-conjugated secondary antibody. Immunoreactive proteins were detected using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific). Reactive bands were detected using enhanced chemiluminescence (ECL) reagents (Thermo). To ensure the equal loading of samples in each lane, membranes were stripped and reprobed with an anti-GAPDH antibody.
Calculation of LIP:LAP ratios
First, intensities of LIP, LAP1, and LAP2 protein bands were quantified using the Quantity One system analysis software (Bio-Rad) including normalization on the basis of the respective loading control. Subsequently, the LIP:LAP ratio was calculated by dividing the LIP value by the respective combined LAP1 and LAP2 value (together denoted as LAP in the LIP:LAP ratio) as previously described (Haas et al., 2010) .
Cell invasion and migration
In vitro invasion and migration assays were performed using Transwell chambers with 8-mm pores (Costar) coated with or without a layer of Matrigel free of growth factors (Collaborative Biomedical). Medium with 20% FBS was added to the lower chambers of the Transwell chamber. Next, 1610 5 -6610 4 cells/well were seeded into the Transwell chambers in triplicate in serum-free medium, followed by incubation at 37˚C for 48 h. The bottom filters were fixed and stained with Crystal Violet at the end of the experiments. Cells in the top chambers were removed by wiping with cotton swabs, and the stained cells that had migrated through the Matrigel were counted under a light microscope. Six randomly selected microscopic fields were counted at 6200 magnification.
ChIP assay
Quantitative ChIP assays were performed using a commercially available Chromatin Immunoprecipitation Kit (Upstate Biotechnology) according to the manufacturer's instructions. Briefly, cells (2.5610 6 per immunoprecipitation) were treated with 1% (w/v) formaldehyde for 10 min at room temperature, and the cross-linking reaction was halted with 0.125 M glycine. The cross-linked chromatin was then sonicated and immunoprecipitated using the rabbit polyclonal anti-C/EBPb antibody. After the reversal of the cross-linking, the precipitated DNA was analyzed by PCR (35 cycles) with two primer pairs (203R1 and 203R2) for the regions of the miR-203 loci containing two potential C/EBPb binding sites and with two negative primer pairs (Neg.ctrl1 and Neg.ctrl2) for the regions without C/EBPb-binding sites. All primers are listed in supplementary material Table S1 .
Electrophoretic mobility shift assay EC109 cells were deprived of serum overnight and incubated with or without EGF for the 24 h before harvesting. Nuclear extracts were prepared using NE-PER TM Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to the manufacturer's instructions. The C/ EBP consensus double-stranded oligonucleotide DNA (59-TGCAGATT-GCGCAATCTGCA-39 annealed with 59-ACGTCTAACGCGTTAGA-CGT-39) (Matsuda et al., 1997) , 203R1 double-stranded oligonucleotide DNA (59-CCTGGGCCTTGCACAACAAGGTGA-39 annealed with 59-TCACCTTGTTGTGCAAGGCCCAGG-39) and 203R2 double-stranded oligonucleotide DNA (59-GCTCCGGGTTGTGAAAGCTGCAGG-39 annealed with 59-CCTGCAGCTTTCACAACCCGGAGC-39) were labeled by 59-biotin. Binding reactions proceeded for 30 min at room temperature with labeled oligonucleotides containing wild-type C/EBPb site complexes formed by LAP and/or LIP were separated by nondenaturing 6.5% PAGE followed by autoradiography using the LightShiftH Chemiluminescent EMSA Kit (Thermo Scientific) according to the manufacturer's instructions. To better identify the three different dimmers (LAP-LAP, LAP-LIP and LIP-LIP), we deliberately made a marker showing different bands in a lane as Piwien-Pilipuk et al. described previously (Piwien-Pilipuk et al., 2001 ). According to their methods, 293FT cells (which lack detectable C/EBPb) were transfected with plasmids pcDNA3-LAP1 (4 mg) plus pcDNA3-LAP2 (4 mg) or pcDNA3-LIP (8 mg). 48 h later, cell lysates enriched in nuclear proteins were prepared.
Immunofluorescence analysis
Cells grown on glass coverslips and tissue slices were fixed in 4% fresh paraformaldehyde (PFA) at room temperature for 15 min and were then washed extensively with PBS to remove PFA, followed by permeabilization with 0.3% Triton X-100 in PBS for 15 min. After incubation in 5% goat serum at 37˚C for 1 h, the cells were incubated with primary antibody overnight, washed with PBS, and incubated with secondary antibody for 1 h at 37˚C. The nucleus was stained with 4,6-diamidino-2-phenylindole (DAPI). The slides were then mounted with fluorescence mounting medium. Photographs were taken using a fluorescence microscope (DP70, Olympus) that was equipped with a digital image capture system.
Statistical analysis
The Student's t-test was used to evaluate the significant difference between groups. All P-values were obtained using a two-tailed statistical analysis, and P,0.05 was considered statistically significant. All data are expressed as mean6s.d.
